

In re: Vitek  
Serial No.: 09/744,133  
Filed: 20 March 2001  
Page 2

### **Claim Amendments**

Please enter the following amended claims:

1 (currently amended). A transgenic mouse whose germ cells and somatic cells contain (i) an inactive endogenous mouse inducible nitric oxide synthase gene, and (ii) a transgene encoding the human inducible nitric oxide synthase gene, said transgene including all regulatory elements of the human nitric oxide synthase gene necessary for a human pattern of expression of said transgene in said transgenic mouse, said human pattern of expression characterized in that lipopolysaccharide (LPS) inducers induce essentially no increase in iNOS activity in phagocytic cells of said mouse as measured by nitric oxide release as compared to the corresponding wild-type mouse.

2 (previously presented). The transgenic mouse according to claim 1, wherein said mouse contains one allele encoding the human inducible nitric oxide synthase gene.

3 (previously presented). A method of determining if a compound is capable of inducing Alzheimer's disease, comprising administering said compound to the transgenic mouse of claim 1, and then examining said mouse for the development of said disease.

4 (previously presented). A method of determining if a compound is capable of inducing Multiple Sclerosis, comprising administering said compound to the transgenic mouse of claim 1, and then examining said mouse for the development of said disease.

5 (previously presented). A method of determining if a compound is capable of inducing Inflammatory Bowel Disease, comprising administering said compound to the transgenic mouse of claim 1, and then examining said mouse for the development of said disease.

6 (previously presented). A method of determining if a compound is capable of inducing Rheumatoid arthritis, comprising administering said compound to the transgenic mouse of claim 1, and then examining said mouse for the development of said disease.

7 (previously presented). A method of screening a compound for activity in treating Alzheimer's disease, comprising administering said compound to the transgenic mouse of claim 1, and then examining said mouse for the treatment of said disease.

8 (previously presented). A method of screening a compound for activity in treating Multiple Sclerosis, comprising administering said compound to the transgenic mouse of claim 1, and then examining said mouse for the treatment of said disease.

9 (previously presented). A method of screening a compound for activity in treating Inflammatory Bowel Disease, comprising administering said compound to the transgenic mouse of claim 1, and then examining said mouse for the treatment of said disease.

10 (previously presented). A method of screening a compound for activity in treating Rheumatoid arthritis, comprising administering said compound to the transgenic mouse of claim 1, and then examining said mouse for the treatment of said disease.

11 (newly presented). The mouse of claim 1, said human pattern of expression further characterized in that said phagocytic cells display low-output nitric oxide release as compared to those of the corresponding wild-type mouse when maximally stimulated.